狠狠色丁香婷婷综合久小说久,国产亚洲精品第一综合另类 ,亚洲av无码精品色午夜飞机馆,国产无套码AⅤ在线观看

法國Oncodesign  
法國藥物發(fā)現(xiàn)和腫瘤藥理學服務公司Oncodesign,Nanocyclix激酶為靶點研究

Founded in 1995 and headed by Dr. Philippe Genne, Oncodesign is a pioneer in the preclinical assessment of anti-cancer therapies, a market that it is leading for many years. Oncodesign's mission consists of discovering effective anti-cancer therapies. Its scientific expertise in pharmacology, imaging and medicinal chemistry, in addition to strong project management skills, support the company's two strategic activities of experimentation and discovery, conducted in partnership with pharmaceutical and biotechnology companies.
The experimentation activity is organized in three technological platforms: PREDICT? specializes in conventional in vitro and in vivo pharmacology; Chi-Mice? focuses on the development of in vivo chimeric humanized models; PharmImage? is dedicated to multimodal, non-invasive pharmaco-imaging. On the basis of these three platforms, Oncodesign markets a broad range of products and services (fee-for-service) for the assessment, validation, targeting and diagnostic linking of anticancer therapies. Since 2010, Oncodesign has incorporated a medicinal chemistry technology into its discovery activity: Nanocyclix?, which is dedicated to the synthesis of highly potent and selective novel kinase inhibitors. The combination of these four technological platforms results in a unique and innovative translational research approach in a risk-sharing approach between partners.